Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $18.84 and traded as high as $20.26. Tandem Diabetes Care shares last traded at $20.07, with a volume of 4,396,478 shares.

Top Tandem Diabetes Care Stories

Investors following TNDM have been watching these stories:

• Positive Sentiment: The FDA cleared Tandem Mobi as the first automated insulin delivery system offering both tubed and tubeless wear options, with up to seven days of wear. Tandem expects to launch the tubeless option in 2027, giving the company a new potential growth opportunity. Article: Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
• Positive Sentiment: Health Canada approved expanded use of Tandem’s t:slim X2 insulin pump with Control-IQ+ technology, extending the product’s availability in Canada. Article: Tandem Diabetes Care Receives Health Canada Approvals
• Neutral Sentiment: The tubeless Mobi launch is planned for 2027, so commercial and financial benefits are prospective rather than immediate. Article: Tandem Mobi FDA Clearance

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TNDM shares. William Blair assumed coverage on Tandem Diabetes Care in a research report on Friday, August 21st. They set an "outperform" rating on the stock. Citigroup reduced their target price on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a "neutral" rating for the company in a research note on Wednesday, September 30th. Truist Financial lowered their target price on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, September 24th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tandem Diabetes Care in a research report on Tuesday, September 8th. Finally, Canaccord Genuity Group set a $40.00 price objective on Tandem Diabetes Care in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $27.18.

Tandem Diabetes Care Stock Performance

The company has a market capitalization of $1.40 billion, a PE ratio of -27.87 and a beta of 1.59. The business's fifty day moving average is $17.40 and its two-hundred day moving average is $18.84. The company has a current ratio of 3.20, a quick ratio of 2.65 and a debt-to-equity ratio of 4.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.15. The business had revenue of $283.69 million for the quarter, compared to analysts' expectations of $265.85 million. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The firm's quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.31) EPS. Equities research analysts predict that Tandem Diabetes Care, Inc. will post -0.61 earnings per share for the current year.

Insider Activity at Tandem Diabetes Care

In related news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the sale, the director directly owned 24,434 shares in the company, valued at approximately $467,911.10. This trade represents a 6.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tandem Diabetes Care

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC boosted its holdings in Tandem Diabetes Care by 157.4% in the second quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company's stock worth $51,058,000 after purchasing an additional 2,068,838 shares during the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 13.0% during the 3rd quarter. GW&K Investment Management LLC now owns 2,903,529 shares of the medical device company's stock valued at $47,357,000 after buying an additional 334,497 shares during the period. Defilade Capital Management L.P. bought a new position in shares of Tandem Diabetes Care during the 1st quarter valued at $14,606,000. Quantinno Capital Management LP boosted its stake in shares of Tandem Diabetes Care by 123.5% in the 1st quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company's stock worth $12,535,000 after buying an additional 361,361 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in shares of Tandem Diabetes Care in the 1st quarter worth $6,570,000.

About Tandem Diabetes Care

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company's offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.